Immune cells in blood may be glioma biomarkers: Study
A study found that analyzing levels of immune cells and related molecules in the bloodstream of people with glioma can accurately distinguish between different…
Steve Bryson, PhD, science writer—
Articles by Steve Bryson
FDA OKs label changes to boost CAR T-cell therapy use for cancer
The U.S. Food and Drug Administration (FDA) has approved label updates for two Bristol Myers Squibb (BMS) CAR T-cell therapies, both for the treatment…
Oral Inqovi, venetoclax for acute myeloid leukemia to be reviewed
The U.S. Food and Drug Administration (FDA) has agreed to review an application for oral Inqovi (decitabine and cedazuridine) in combination with oral venetoclax for…
Cell therapy anito-cel extends treatment-resistant RRMM survival
Nearly all the people with relapsed or refractory multiple myeloma (RRMM) who took part in a Phase 2 clinical trial responded to the cell…
Exportin-1 function may explain blood cancer treatment side effects
Exportin-1, a therapeutic target for nuclear export inhibitors — a class of drugs used to treat blood cancers including multiple myeloma and leukemia…
Orca-T outperforms standard stem cell transplant for blood cell cancer
Orca-T, Orca Bio‘s investigational allogeneic stem cell transplant for treating blood cell cancers, more than doubled the rate of survival free from moderate…
FDA grants orphan drug status to PEP-010 for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Pep-Therapy‘s PEP-010, a potential first-in-class treatment for pancreatic cancer. The…
Repurposed avapritinib reduced tumor size in hard-to-treat gliomas
Avapritinib, an approved orally available medication, reduced tumor size in a subset of children and young adults with treatment-resistant high-grade gliomas, a study shows.
2nd Iceland Cycling Expedition aims to raise myeloma research funds
The International Myeloma Foundation (IMF) has announced its 2nd annual Iceland Cycling Expedition (ICE), a seven-day endurance bike ride to raise funds for…
Treatment, outcomes poorer in AML with chromosome abnormality
Chromoanagenesis — an abnormal rearrangement of DNA within the chromosomes of certain cells, including blood cells — links with limited treatment response and poorer outcomes…
